The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.

@article{Coffey2014TheNK,
  title={The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.},
  author={Greg P. Coffey and Andreas Betz and Francis R Deguzman and Yvonne Pak and Mayuko Inagaki and Dale C Baker and Stanley J. Hollenbach and Anjali Pandey and Uma Sinha},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2014},
  volume={351 3},
  pages={538-48}
}
The heterogeneity and severity of certain autoimmune diseases and B-cell malignancies warrant simultaneous targeting of multiple disease-relevant signaling pathways. Dual inhibition of spleen tyrosine kinase (SYK) and Janus kinase (JAK) represents such a strategy and may elicit several benefits relative to selective kinase inhibition, such as gaining control over a broader array of disease etiologies, reducing probability of selection for bypass disease mechanisms, and the potential that an… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 62 references

A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers

  • DS Hong, A Younes, +7 authors M Yamashita
  • J Clin Oncol
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…